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Abstract
Background: A high level of comorbidity at dialysis initiation is associated with an increased risk of death.
However, contemporary assessments of the validity and prognostic value of comorbidity indices are lacking.
Objectives: To assess the validity of two comorbidity indices and to determine if a high degree of comorbidity is
associated with mortality among dialysis patients.
Design: Cohort study.
Setting: QEII Health Sciences Centre (Halifax, Nova Scotia, Canada).
Patients: Incident, chronic dialysis patients between 01 Jan 2006 and 01 Jul 2013.
Measurements: Exposure: The Charlson Comorbidity Index (CCI) and End-Stage Renal Disease Comorbidity Index
(ESRD-CI) were used to classify individual comorbid conditions into an overall score. Comorbidities were classified
using patient charts and electronic records.
Outcome: All-cause mortality.
Confounders: Patient demographics, dialysis access, cause of ESRD and baseline laboratory data.
Methods: Regression coefficients were estimated on the CCI and ESRD-CI. Discrimination for death was assessed
using Harrell’s c-index. Adjusted Cox proportional hazard models were used to calculate relative hazards and 95 %
confidence intervals for each category of the CCI and ESRD-CI.
Results: The cohort consisted of 771 ESRD patients from 01 Jan 2006 to 01 Jul 2013. Most were male (62 %) and
Caucasian (91 %). The cohort had a high proportion of diabetes (48 %), history of previous myocardial infarction
(31 %) and heart failure (22 %). Regression coefficients on the CCI and ESRD-CI were 0.55 and 0.52, respectively. The
c-index, for the prediction of death, was 0.61 for the CCI and 0.63 for the ESRD-CI. ESRD-CI scores of 4, 5 and ≥6
were associated with a similar mortality risk (adjusted relative hazard of 1.95, 1.89 and 1.99, respectively). There was
a small increased mortality risk for CCI scores of 4, 5 and ≥6 (adjusted relative hazard of 1.86, 2.38 and 2.71,
respectively).
Limitations: Classification of comorbidities for each patient was determined by clinical impression.
Conclusions: The CCI and ESRD-CI have a limited ability to discriminate mortality risk for incident dialysis patients.
Acknowledging the frequency with which they are used, this study emphasizes the need to re-examine the
usefulness of previously derived comorbidity indices in contemporary dialysis cohorts.
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Résumé
Contexte: Un taux élevé de comorbidité en début de dialyse est lié à un risque accru de mort. Toutefois, rares sont
les évaluations récentes de la validité et de la valeur pronostique des indices de comorbidité.
Objectifs: Vérifier la validité de deux indices de comorbidité et déterminer la relation entre un taux élevé de
comorbidité et le taux de mortalité chez les patients dialysés.
Type d’étude: Étude de cohorte.
Contexte: Centre des sciences de la santé QEII (Halifax, Nouvelle-Écosse, Canada).
Participants: Patients incidents en dialyse chronique du 1er janv. 2006 au 1er juil. 2013.
Mesures: Exposition: L'indice de comorbidité Charlson (CCI) et l'indice de comorbidité au stade terminal
d'insuffisance rénale (ESRD-CI) ont servi à la mesure de la comorbidité, à la lumière des fiches et des dossiers
électroniques des patients.
Résultat: Taux de mortalité, toutes causes confondues.
Facteurs de confusion: caractéristiques sociodémographiques des patients, accès à la dialyse, cause de l'insuffisance
rénale terminale (IRT) et données de référence du laboratoire.
Méthodes: On a procédé à l'estimation des coefficients de régression du CCI et de l'ESRD-CI, puis à l'évaluation du
seuil de mortalité à l'aide de l'indice C de Harrell. On a enfin utilisé des modèles des risques proportionnels de Cox
ajustés afin de calculer les risques relatifs et les intervalles de confiance à 95 % pour chaque catégorie du CCI et de
l'ESRD-CI.
Résultats: La cohorte comprenait 771 patients en IRT du 1er janv. 2006 au 1er juil. 2013. La plupart étaient des
hommes (62 %) de race blanche (91 %). On y trouvait une proportion élevée de diabète (48 %), d'infarctus du
myocarde antérieur (31 %), et d'insuffisance cardiaque (22 %). Les coefficients de régression du CCI et de l'ESRD-CI
indiquaient 0,55 et 0,52, respectivement. L'indice C du risque de décès était de 0,61 pour le CCI et de 0,63 pour
l'ESRD-CI. Pour ce dernier indice, des valeurs de 4, 5 et 6 ou plus étaient liées à un risque de mortalité équivalent
(risque relatif ajusté de 1,95, de 1,89 et de 1,99, respectivement). On a noté une légère augmentation du risque de
mortalité pour les valeurs du CCI de 4, 5 et 6 ou plus (risque relatif ajusté de 1,86, de 2,38 et de 2,71,
respectivement).
Limites: Le classement des comorbidités de chaque patient était déterminé par opinion clinique.
Conclusions: Le CCI et l'ESRD-CI sont limités en ce qui a trait à la capacité de déterminer le risque de mortalité
chez une population incidente dialysée. En regard de la fréquence d’utilisation de la dialyse, la présente étude
souligne le besoin de réévaluer l'utilité des indices de comorbidité précédemment dérivés des récentes cohortes
dialysées.
What was known before
The Charlson Comorbidity Index (CCI) and End-Stage
Renal Disease Comorbidity Index (ESRD-CI) are com-
monly used in studies of dialysis patients, but assess-
ments of their validity are lacking.
What this adds
Both indices had a limited ability to discriminate mortal-
ity risk in this study emphasizing that they may not be
the best method of risk adjustment in contemporary dia-
lysis cohorts.
Introduction
In patients with end-stage renal disease (ESRD), the
presence of comorbid conditions has been shown to
have a negative impact on survival [1–3]. A commonly
used approach for summating individual conditions into
an overall “score” of comorbidity for risk stratification is
calculation of the Charlson Comorbidity Index (CCI) [4].
The CCI was initially derived in a cohort of 559 patients,
and tested in a second cohort of 680 patients followed for
10 years [4]. In the original study, 19 comorbid conditions
were evaluated in a Cox proportional hazards model.
Point scores were assigned to each comorbidities hazard
ratio depending on the value. The sum of the points
equalled a given individuals’ overall CCI score. A higher
CCI score is associated with an increased mortality risk in
ESRD patients [5–12], however the CCI does have limita-
tions when applied to ESRD patients. The inclusion of
renal disease as one of the component comorbidities is re-
dundant and medical advances since the development of
the CCI have changed the prognosis of some of the indi-
vidual comorbid conditions within the index [13].
There have been a number of additional comorbidity in-
dices that have been created for ESRD patients [1, 14–16],
including the End Stage Renal Disease Comorbidity Index
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(ESRD-CI) which avoids some of the limitations associ-
ated with the original CCI [15]. Having been designed as
an adaptation of the CCI, the ESRD-CI was developed in a
cohort of 237 incident dialysis patients [15]. 15 of the 19
conditions in the CCI were evaluated in a multivariable
Cox survival analysis. Similar to the CCI, point scores
were assigned to each condition’s hazard ratio and
summed for each individual in the derivation cohort. In
the model derivation study the ESRD-CI had slightly bet-
ter performance characteristics compared to the CCI in
the tested population (c-statistic of 0.73 versus 0.72) [15].
While both the CCI and ESRD-CI are frequently used
for risk adjustment in studies of dialysis patients [17–22],
only a few studies have attempted to validate either index
[15, 23, 24]. In addition, these validation studies have limi-
tations including incomplete inclusion of all necessary co-
morbid conditions, and validation techniques that are not
specific to time-to-event analyses [15, 23, 24]. Finally, val-
idation in a more recent era-cohort (acknowledging that
patient characteristics, disease prevalence and outcome
after dialysis initiation may differ from those in older co-
horts) has not been conducted in many studies. A lack of
validity/limited prognostic ability of either index will
emphasize the need to re-examine the usefulness of previ-
ously derived comorbidity indices in contemporary dialy-
sis cohorts.
Therefore, the purpose of this study was to assess the
validity of the CCI and ESRD-CI in a contemporary co-
hort of ESRD patients, and to determine if a high degree
of comorbidity was independently associated with mor-
tality. We hypothesized that both indices would have a
reduced level of discrimination compared to the deriv-
ation studies, but that increased comorbidity burden




We conducted a cohort study of incident, adult (≥18 years)
chronic dialysis patients in a large tertiary care institute
between 1 Jan 2006 and 01 Jul 2013. Follow-up for pa-
tients began at the initial start date for their dialysis.
Exposure definition
Comorbidity data was collected at the start of dialysis in
all patients in a prospective manner, using documentation
in patient charts (dating back to the first nephrology visit)
and electronic records by the patients’ primary nephrolo-
gist. Comorbidities were subsequently verified in all pa-
tients by two nephrologists (K.T. and B.K.) and one
nephrology trainee (T.A.). All 19 individual comorbid con-
ditions in the CCI were collected at the time of dialysis
initiation and scored according to the CCI derivation
study. ESRD-CI scores were retrospectively calculated by
re-scoring the comorbidities comprising the ESRD-CI
based on the derivation paper. ESRD-CI scores were ana-
lyzed as ordinal variables and after categorization into six
groups to be consistent with the derivation paper (using
scores of 0/1, 2, 3, 4, 5 and ≥6) [15]. The CCI was ana-
lyzed both as an ordinal variable and in categories (2, 3,
4, 5 and ≥6). Since all patients in our dataset had ESRD,
the lowest possible CCI score was 2.
In addition to the CCI and ESRD-CI scores, demo-
graphic data (age, race, gender), dialysis access (central
venous catheter or arteriovenous fistula) type of dialysis
modality (peritoneal or hemodialysis), cause of ESRD
(diabetes, glomerulonephritis, hypertension, other) and
baseline laboratory data (hemoglobin, phosphate, estimated
glomerular filtration rate and albumin) were collected on
all patients at the start of dialysis using a combination of
electronic records and paper chart review.
Outcome
The primary outcome was all cause mortality after dialy-
sis initiation. Administrative censoring was imposed on
01 Jan 2014. Patient survival was censored at the date of
transplantation.
Statistical analysis
Descriptive statistics for baseline characteristics of the study
cohort were reported as counts with proportions, mean
with standard deviation and median with interquartile
range for categorical, normally distributed continuous and
non-normally distributed continuous variables, respectively.
External validation of the CCI and ESRD-CI followed the
methods previously described by Royston et al. based on
availability of data in the original derivation studies [25]:
1. Regression coefficients were estimated on the CCI
and ESRD-CI (defined as the precise CCI and
precise ESRD-CI).
2. Regression coefficients were also estimated on the
categorical CCI (2, 3, 4, 5 and 6+) and ESRD-CI (0/1,
2, 3, 4, 5 and 6+) as a secondary analysis (defined as
the categorical CCI and categorical ESRD-CI).
3. Discrimination (defined as the level of concordance
between the risk predicted by a model and the rate of
events experienced [25]) was assessed for the precise
and categorical CCI as well as the precise and
categorical ESRD-CI using Harrell’s c-index. Harrell’s
c-index assesses the fraction of all possible pairings of
patients in which the predictions and outcomes
are concordant [26]. Scores range from 0.5 (no
discrimination), to 1.0 (perfect discrimination). As
a reference, the CHADS2 score for atrial fibrillation
stroke risk has a reported c-index of 0.683 [27].
4. Kaplan-Meier Survival curves were plotted for each
category of CCI/ESRD-CI and discrimination was
Gomez et al. Canadian Journal of Kidney Health and Disease  (2015) 2:34 Page 3 of 9
also visually assessed according to the ordering and
separation of the curves.
Cox proportional hazard models were used to calculated
relative hazards and 95 % confidence intervals for each
category of the CCI and ESRD-CI. Proportionality of haz-
ards was assessed using Schoenfeld Residuals. Multivari-
able models included variables based on clinical judgment
and those derived from the literature as being associated
with mortality in studies of dialysis patients including age
[28], gender [29], Caucasian versus non-Caucasian race
[28, 30], dialysis modality [31], cause of ESRD, albumin
[32], hemoglobin [33], phosphate [34, 35] and modifica-
tion of diet in renal disease (MDRD) estimated glomerular
filtration rate [36]. A two sided P value of <0.05 was the
threshold for statistical significance. Approval to conduct
this study was granted by our institutional research ethics
board (Nova Scotia Health Authority, CDHA-RS/2014-
288). All analyses were conducted using Stata version
12.0, College Station, TX, USA.
Results
Baseline characteristics
The cohort consisted of 771 ESRD patients from 01 Jan
2006 to 01 Jul 2013. Baseline characteristics of the co-
hort are noted in Table 1. The majority of patients were
male (62 %) and Caucasian (91 %). Common comorbidi-
ties included diabetes (48 %), previous myocardial infarc-
tion (31 %), congestive heart failure (22 %) and
peripheral vascular disease (20 %). The median CCI
score was 4 (Q1-Q3: 3–6), and the median ESRD-CI
Score was 2 (Q1-Q3: 0–4).
Validation
Cox regression on the precise CCI and ESRD-CI revealed
coefficients of 0.55 (SE 0.08) and 0.52 (SE 0.07), respect-
ively (Table 2). Cox regression on the categorical CCI and
ESRD-CI revealed similar coefficients (0.56 and 0.52, re-
spectively). The c-index was 0.61 (SE 0.02) for both the
precise and categorical CCI, and 0.63 (SE 0.02) and 0.62
(SE 0.02) for the precise and categorical ESRD-CI (Table 2).
Kaplan-Meier survival curves for each ESRD-CI score cut-
off are displayed in Fig. 1 (Log-rank P < 0.001). There was
separation of the curves for patients with a high versus low
Table 1 Baseline characteristics of the cohort
Demographics
Age (mean years ± SD) 62.6 ± 15.1
Male, n (%) 479 (62.1)
Caucasian, n (%) 702 (91.1)






Polycystic kidney disease 60 (7.8)
aSelect Comorbidities, n (%)
Diabetes with complications 286 (37.1)
Myocardial infarction 236 (30.6)
Congestive heart failure 172 (22.3)
Peripheral vascular disease 154 (20.0)
Chronic lung disease 129 (16.7)
Cerebrovascular disease 93 (12.1)
Diabetes without complications 81 (10.5)
Neoplasia 50 (6.5)
Peptic ulcer disease 49 (6.4)
Laboratory
MDRD GFR [median mL/min/1.73 m2 (Q1-Q3)] 8 (6–10)
Albumin (mean g/dL ± SD) 3.14 ± 0.65
Phosphate, n = 768 [median mg/dL (Q1-Q3)] 5.9 (5.0-7.4)
Hemoglobin, n = 770 [median g/dL (Q1-Q3)] 9.7 (8.6-10.9)
Dialysis Access, n (%)
Hemodialysis with central venous catheter 410 (53.2)
Hemodialysis with arteriovenous fistula 194 (25.2)
Peritoneal dialysis 167 (21.7)
End Stage Renal Disease Comorbidity Index, n (%)
Index score of ≤1 253 (32.8)
Index score of 2 161 (20.9)
Index score of 3 62 (8.0)
Index score of 4 92 (11.9)
Index score of 5 59 (7.7)
Index score of ≥6 144 (18.7)
Charlson Comorbidity Index, n (%)
Index score of ≤1 0 (0)
Index score of 2 189 (24.6)
Table 1 Baseline characteristics of the cohort (Continued)
Index score of 3 100 (13.0)
Index score of 4 152 (19.7)
Index score of 5 120 (15.6)
Index score of ≥6 210 (27.2)
aRemaining comorbid conditions comprising the CCI and ESRD-CI (rheumatological,
dementia, mild liver disease, moderate/severe liver disease, metastatic disease,
leukemia, lymphoma, human immunodeficiency virus) were present in less than
5 % of the dialysis population at dialysis initiation)
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score (6+ versus 0/1 or 2). However, discordance was ob-
served for patients with an intermediate score. A similar
finding was noted for the CCI, however, there was slightly
more separation between the curves in an incremental
fashion based on score (Fig. 2).
Mortality
Over 1796.6 patient years at risk, there were 311 deaths.
The distribution of deaths stratified by CCI and ESRD-
CI scores are graphically displayed in Fig. 3. There was a
rise in the number of deaths and fall in the number of pa-
tients that received a kidney transplant with each ESRD-
CI score cut-off. In an unadjusted Cox survival analysis,
relative to patients with an ESRD-CI score of ≤1, those
with scores of ≥6 had a mortality HR of 2.64 (95 % CI 1.91
to 3.65, p < 0.001, Table 3). A similar mortality HR was ob-
served for patients with CCI scores of ≥6 compared to 2
(HR 2.91, 95 % CI 2.04 to 4.15, p < 0.001). After multi-
variable adjustment, there was attenuation in the HR.
Similar HR’s were noted for patients with scores of 4–6
for the ESRD-CI. For the CCI, there was separation in
the HR’s for scores of 4–6 however, confidence inter-
vals overlapped (Table 3).
Discussion
In this cohort study we evaluated the ability of the CCI
and ESRD-CI to predict mortality in a population of in-
cident dialysis patients. The association between comor-
bidity and mortality in our dataset was not as strong as
in the derivation cohorts. In addition although higher
comorbidity burden using the CCI and ESRD-CI was as-
sociated with mortality after multivariable adjustment,
there was not a large separation in mortality risk when
evaluating incremental changes in comorbidity scores.
We can speculate that the limited utility of the CCI and
ESRD-CI is due to several potential underlying reasons;
limited generalizability of both indices, variability in co-
morbidity classification and comorbidity prevalence
within either cohort, limitations with respect to deriv-
ation (including statistical over-fitting) and limited utility
of comorbidity indices in general.
Limited generalizability may explain the observation of
only partial validity. The CCI and ESRD-CI used a rela-
tively small population from a single geographical area
and validation in this study occurred in a separate single
geographical area. Differences in the determinants of
health in two communities may contribute to the different
outcomes of two dialysis patients with similar comorbidi-
ties. Social determinants of health, in particular, have been
Table 2 Cox regression coefficients and c-index for precise and
categorical CCI/ESRD-CI
Index Regression coefficient [95 % CI] c-index
Precise CCI 0.55 [0.38-0.71] 0.61
Categorical CCI 0.56 [0.39-0.72] 0.61
Precise ESRD-CI 0.52 [0.38-0.66] 0.63
Categorical ESRD-CI 0.52 [0.38-0.66] 0.62
Fig. 1 Kaplan-Meier survival curves for time to death stratified by
ESRD-CI Score groups
Fig. 2 Kaplan-Meier survival curves for time to death stratified by
CCI Score groups
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shown to impact mortality rates in patients with ESRD
[37–39]. More recently, frailty has been shown to be an
important prognostic factor for incident dialysis patients
[40]. Therefore, prediction models that incorporate clin-
ical, demographic and social factors as well as assessments
of frailty may be more applicable to ESRD cohorts [41].
An attempt at further validation of this index in a national
or international sample of patients from a number of dif-
ferent centers in different geographic regions might help
to clarify its generalizability and provide a clearer picture
of its clinical utility.
There were notable characteristic differences compar-
ing patients in our dataset and the dataset of the original
studies, which may explain the reduced discrimination.
Our cohort was in a more recent era (2006–2013), and
the relative impact of some comorbid conditions may
have changed [42–45]. The mortality risk in our cohort
was higher than either derivation cohort [15] however;
certain comorbidities such as chronic lung disease
(16.7 % vs. 27.4 %) and neoplasia (6.5 % vs. 12.2 %) were
less common in our cohort [15]. Furthermore, there was a
reduced prevalence of overall comorbidity compared to
the derivation cohorts. This reduced burden of disease
might have affected the predictive value of the individ-
ual comorbidities comprising both indices. Alterna-
tively, under-reporting of individual health conditions
in each cohort may have explained the observed differ-
ences. For example, if comorbidity in our validation co-
hort was under-reported, despite a “falsely low” burden
of comorbidity patients would have continued to have a
high mortality rate. This in turn would have reduced
the discrimination in our dataset.
The derivation of the CCI or ESRD-CI may have also
impacted its validation. The linear predictor from a Cox
model is ideal for developing a prognostic index. The
linear predictor is described as the weighted sum of the
variables in the model, where the regression coefficients
are the weights [25]. In the development of the CCI,
(which was replicated in the derivation of the ESRD-CI
to maintain consistency) scoring weights were assigned
to each HR derived from the Cox model [4, 15]. This
may lead to over-weighting of conditions with high haz-
ard ratios but limited precision and marked variability
around the estimate.
While there are limitations with the comorbidity indi-
ces, it is important to acknowledge that both indices did
have some validity. It is not unexpected that a higher
level of comorbidity would be associated with a higher
risk of death among dialysis patients, however most
evaluations of comorbidity scores look at short term
mortality or use validation techniques that do not in-
corporate survival time [15, 19, 23, 24]. Discrimination
was lower in our validation dataset, however, the relative
hazard for death was proportional across the index and
the mortality association using either index persisted
despite a relatively long duration of follow-up. Further-
more, it is not uncommon for validation studies to iden-
tify some reduction in predictive value [46] In addition
there are other features of these indices that make them
valuable. Both are intuitive; comorbid conditions that
would be expected to confer a higher hazard for mortal-
ity are weighted more heavily. The major exception to
this would be HIV (a component of the original CCI) a
condition with a lower contemporary mortality rate [42].
Fig. 3 Distribution of outcomes stratified by Comorbidity Index Score groups
Gomez et al. Canadian Journal of Kidney Health and Disease  (2015) 2:34 Page 6 of 9
Another advantage is that both indices draw on clinical
data that is often present in patient charts, making them
practical tools that do not necessarily require other diag-
nostic testing or laboratory investigation. Finally, the as-
sociation with mortality persisted in our study even after
multivariable adjustment for known predictors of mor-
tality among dialysis patients.
It is important to note that there are limitations of co-
morbidity indices in general that warrant consideration.
Most indices do not fully take into account the stage of
progression, severity or proximity of the comorbid con-
dition in relation to dialysis initiation [1, 14–16].
Furthermore, accumulation of comorbidity that often ac-
companies the early period after dialysis initiation [47] is
not typically included in comorbidity indices. Global
scoring systems that incorporate all prior comorbidi-
ties are easier to calculate and extract from patient re-
cords and facilitate ease of clinical application at
point-of-care. More novel indices such as the Adult
Comorbidity Evaluation-27, which takes into account
the proximity and severity of the comorbidity, have
been shown to out perform the CCI at predicting mor-
tality [48, 49] and may be better suited for dialysis co-
horts. Additionally, simple prognostic models that
Table 3 Multivariable Cox survival analysis for the ESRD-CI and CCI
Model ESRD-CI Group Events (N) HR [95 % CI] Model CCI Group Events (N) HR [95 % CI]
Unadjusted ≤12 311 (ref)1.74 [1.22 to 2.50] Unadjusted 12 311 —(ref)
3 1.39 [0.94 to 2.07] 3 1.84 [1.17 to 2.90]
4 2.32 [1.62 to 3.32] 4 1.83 [1.23 to 2.72]
5 2.37 [1.60 to 3.52] 5 2.31 [1.54 to 3.47]
≥6 2.64 [1.91 to 3.65] ≥6 2.91 [2.04 to 4.15]
Model 1a ≤12 311 (ref)1.60 [1.12 to 2.30] Model 1a 12 311 —(ref)
3 1.19 [0.80 to 1.76] 3 1.64 [1.04 to 2.59]
4 2.00 [1.40 to 2.86] 4 1.66 [1.12 to 2.47]
5 1.97 [1.32 to 2.93] 5 2.12 [1.41 to 3.18]
≥6 2.12 [1.52 to 2.93] ≥6 2.44 [1.71 to 3.49]
Model 2b ≤12 311 (ref)1.62 [1.13 to 2.33] Model 2b 12 311 —(ref)
3 1.21 [0.81 to 1.80] 3 1.66 [1.05 to 2.63]
4 2.02 [1.41 to 2.90] 4 1.69 [1.14 to 2.52]
5 1.99 [1.33 to 2.96] 5 2.13 [1.42 to 3.21]
≥6 2.11 [1.52 to 2.93] ≥6 2.47 [1.73 to 3.53]
Model 3c ≤12 311 (ref)1.60 [1.11 to 2.30] Model 3c 12 311 —(ref)
3 1.21 [0.80 to 1.81] 3 1.64 [1.03 to 2.59]
4 2.02 [1.40 to 2.93] 4 1.86 [1.23 to 2.81]
5 1.91 [1.27 to 2.90] 5 2.29 [1.48 to 3.54]
≥6 2.09 [1.49 to 2.93] ≥6 2.75 [1.86 to 4.08]
Model 4d ≤12 311 (ref)1.57 [1.09 to 2.27] Model 4d 12 311 —(ref)
3 1.20 [0.80 to 1.80] 3 1.63 [1.03 to 2.59]
4 1.97 [1.36 to 2.87] 4 1.83 [1.21 to 2.77]
5 1.86 [1.23 to 2.81] 5 2.24 [1.44 to 3.47]
≥6 2.06 [1.46 to 2.89] 6 2.70 [1.81 to 4.02]
Model 5e ≤12 309 (ref)1.63 [1.12 to 2.36] Model 5e 12 309 —(ref)
3 1.28 [0.84 to 1.91] 3 1.76 [1.10 to 2.82]
4 1.95 [1.34 to 2.85] 4 1.86 [1.22 to 2.83]
5 1.89 [1.25 to 2.86] 5 2.38 [1.53 to 3.72]
≥6 1.99 [1.41 to 2.81] ≥6 2.71 [1.81 to 4.06]
a: Adjusted for age
b: Adjusted for factors in a., race and gender
c: Adjusted for factors in b. and cause of ESRD
d: Adjusted for factors in c. and dialysis type
e: Adjusted for factors in d. and laboratory data (MDRD GFR, albumin, phosphate, hemoglobin)
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include the “surprise question” have also been shown
to accurately predict survival for patients receiving
hemodialysis [50].
This study utilized a substantial Canadian cohort and a
long follow up time while leveraging electronic medical
records to ensure a high quality and robust dataset. Add-
itionally validation of the index was performed utilizing
stringent methodology [25]. Examining the adjusted asso-
ciation between the CCI and ESRD-CI and mortality was
enhanced by the relatively large number of outcomes.
There are, however, limitations to this study. The clas-
sification of comorbidities for each patient was deter-
mined by clinical impression (based on documentation
in paper chart and electronic records). This introduces
the possibility for misclassification bias. The derivation
cohort(s) would have also been affected by misclassifica-
tion bias, potentially compounding the observed differ-
ences in disease prevalence and prognostic utility. Our
ability to completely validate either index was limited by
the level of information provided in the original studies.
In particular, an assessment of calibration (the ability of
the index to assign the correct event probability at any
relevant follow-up time and every level of predicted risk
[25]) could not be performed.
Conclusion
The CCI and ESRD-CI had a limited ability to discrimin-
ate risk of death for incident dialysis patients in a contem-
porary Canadian cohort. Although a higher comorbidity
burden was associated with mortality, incremental in-
creases in index scores did not considerably change the
risk of death.
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